Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies

Table 1

Some of the TKIs currently used for the treatment of MTC in clinical trials and off-label.

Drug	Oral daily dose	Major targets
Vandetanib	100–300 mg	VEGFR-1, VEGFR-2, VEGFR-3, RET, EGFR
Sorafenib	400–800 mg	RET, VEGFR-2, VEGFR-3, Flt-3, PDGFRβ, KIT, RAF-1
Sunitinib	37.5 mg every day; 50 mg daily 4 weeks on 2 weeks off	VEGFR-2, PDGFRβ, KIT, RET
Cabozantinib (XL184)	125–175 mg/day	MET, VEGFR-2, RET, KIT, Flt-3, Tie-2
E7080	24 mg	VEGFR-2, VEGFR-3, VEGFR-1, KIT, FGFR1, PDGFR, EGFR